167074-97-7

Basic information

• Product Name: 10-Oxo Docetaxel
• Synonyms: 10-Oxo Docetaxel;(αR,βS)-;Docetaxel IMpurity B (10-Oxo Docetaxel;Docetaxel EP Impurity B
• CAS NO: 167074-97-7
• Molecular Formula: C43H51NO14
• Molecular Weight: 805.86334
• Product Categories: Chiral Reagents;Intermediates;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 167074-97-7.mol

Chemical Properties

• Melting Point: 152-158°C
• Boiling Point: 887.3±65.0 °C(Predicted)
• Appearance: /
• Density: 1.37±0.1 g/cm3 (20 ºC 760 Torr)
• Refractive Index: 1.614
• Storage Temp.: Hygroscopic, -20?C Freezer, Under Inert Atmosphere
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 11.19±0.46(Predicted)
• Stability: Epimerize In Solution, Hygroscopic
• CAS DataBase Reference: 10-Oxo Docetaxel(CAS DataBase Reference)
• NIST Chemistry Reference: 10-Oxo Docetaxel(167074-97-7)
• EPA Substance Registry System: 10-Oxo Docetaxel(167074-97-7)

Safety Data

• Hazardous Substances Data: 167074-97-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
10-Oxo Docetaxel is used as an intermediate in the synthesis of Docetaxel for its remarkable anti-tumor properties. It plays a crucial role in the development of cancer treatment drugs, particularly for the production of Docetaxel, which is effective against various types of cancer.
Used in Cancer Treatment:
10-Oxo Docetaxel is used as a precursor in the production of Docetaxel, a potent chemotherapeutic agent. It contributes to the development of cancer-fighting drugs that can be used to treat a wide range of malignancies, including breast, lung, gastric, and prostate cancers, among others.
Used in Research and Development:
10-Oxo Docetaxel is utilized in research and development for the study of taxoid compounds and their potential applications in cancer therapy. Its unique chemical properties and anti-tumor effects make it a valuable subject for scientific investigation and the development of new cancer treatments.

InChI:InChI=1/C43H51NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30,32-33,35,46,48,53H,19-21H2,1-8H3,(H,44,52)/t26?,27-,28+,30-,32?,33-,35?,41+,42-,43+/m0/s1

Upstream product

• 114915-20-7 Docetaxel 

Relevant articles and documents

Preparation method 10 - carbonyl docetaxel

The invention discloses a preparation method of 10 - carbonyl docetaxel, and the technical scheme of the invention comprises the following steps: S1: dissolving docetaxel solvent, adding heavy metal salt, stirring and reacting, carrying out suction filtra

PHARMACEUTICAL COMPOSITION CONTAINING A TAXANE DERIVATIVE, DESTINED FOR THE PREPARATION OF AN INFUSION SOLUTION, METHOD OF PREPARATION THEREOF AND USE THEREOF

A pharmaceutical composition containing a taxane derivative, destined for the preparation of an infusion solution for administration to patients, containing a concentrate consisting of a pharmaceutically effective amount of docetaxel, a suitable solvent,

Synthesis and evaluation of C-seco paclitaxel analogues

Starting from 7,9diTes-10-dehydro C-secobaccatin III (4a), C-seco analogues of paclitaxel retaining biological activity were synthesised.